title: Dopamine D(2) receptors mediate amylin's acute satiety effect.
abstract: The anorectic effect of the pancreatic peptide amylin has been established in numerous studies. Here, we investigated the influence of a pretreatment with dopamine (DA) D(1)- and D(2)-receptor antagonists on the anorectic effect of intraperitoneally injected amylin in rats fed a medium-fat (18% fat) diet. In 24-h food-deprived rats, pretreatment with the DA D(2)-receptor antagonist raclopride [100 microg/kg (0.2 micromol/kg) ip] significantly attenuated amylin's (5 microg/kg ip) anorectic effect, whereas raclopride alone had no effect on food intake [i.e., food intakes 1 h after injection were (n = 12): NaCl/NaCl 7.3 +/- 0.5 g; NaCl/amylin 3.9 +/- 0.6; raclopride/NaCl 7.7 +/- 0.7; raclopride/amylin 5.6 +/- 0.7]. Pretreatment with another DA D(2) receptor antagonist, sulpiride [50 mg/kg (154 micromol/kg) ip], similarly reduced amylin's satiety effect, whereas pretreatment with the DA D(1)-receptor antagonist SCH-23390 [10 microg/kg (0.03 micromol/kg) ip] did not influence amylin's effect. SCH-23390, however, completely blocked the anorexia induced by D-amphetamine (0.3 mg/kg ip). These results suggest that, under the present feeding conditions, the dopaminergic system mediates part of amylin's inhibitory effect on feeding in rats when administered intraperitoneally. This seems to involve DA D(2) receptors but not D(1) receptors.
authors.affiliation: Institute of Veterinary Physiology, University of Zurich, 8057 Zurich, Switzerland. tomlutz@vetphys.unizh.ch
authors.forename: T A
authors.initials: TA
authors.lastname: Lutz
authors.forename: S
authors.initials: S
authors.lastname: Tschudy
authors.forename: A
authors.initials: A
authors.lastname: Mollet
authors.forename: N
authors.initials: N
authors.lastname: Geary
authors.forename: E
authors.initials: E
authors.lastname: Scharrer
mesh_terms: D000682:Amyloid / Q000494:pharmacology / Q000502:physiology*; D000818:Animals; D000855:Anorexia / Q000139:chemically induced / Q000503:physiopathology; D001552:Benzazepines / Q000494:pharmacology; D002940:Circadian Rhythm; D003913:Dextroamphetamine; D015259:Dopamine Agents; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D004435:Eating / Q000187:drug effects; D005508:Food Deprivation / Q000502:physiology; D007274:Injections, Intraperitoneal; D058228:Islet Amyloid Polypeptide; D008297:Male; D020891:Raclopride / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D012528:Satiety Response / Q000187:drug effects / Q000502:physiology*; D013469:Sulpiride / Q000494:pharmacology
chemical_list: D000682:Amyloid; D001552:Benzazepines; D015259:Dopamine Agents; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D058228:Islet Amyloid Polypeptide; D017448:Receptors, Dopamine D2; D020891:Raclopride; D013469:Sulpiride; D003913:Dextroamphetamine